Skip to main content
Premium Trial:

Request an Annual Quote

Euformatics Partners With Cerba, Inks Distribution Deal With Appolon Bioteck

NEW YORK – Finnish bioinformatics firm Euformatics said on Tuesday that it has partnered with French clinical lab firm Cerba on next-generation sequencing test validation. Separately, Euformatics said Appolon Bioteck will distribute its software in France.

Under the terms of the Cerba deal, Euformatics will provide its Genomics Hub software suite for NGS test validation as well as evidence-based quality metrics for different NGS platforms. Financial and other details were not disclosed.

"We were impressed by the insight that the Euformatics team has on NGS data from a technical and analytical perspective," Cerba Medical Director Benedicte Roquebert said in a statement. "Their software tools were a great fit for us as we are expanding our lab infrastructure with new sequencers and needed a kit- and sequencer-agnostic solution to enable our geneticists to efficiently diagnose patient samples."

Terms of Euformatics' deal with Appolon Bioteck to market NGS data analysis tools in France were also not disclosed.

Earlier this year, Euformatics signed a distribution deal with Zahrawi Group covering Bahrain, Oman, and the United Arab Emirates.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.